Viral cancer therapies: are they ready for combination with other immunotherapies?
- 4 August 2017
- journal article
- editorial
- Published by Taylor & Francis in Future Oncology
- Vol. 13 (18) , 1569-1571
Abstract
International audienceno abstracKeywords
Funding Information
- ‘La Fondation pour la Recherche Médicale
- ’ ‘La Ligue Contre le Cancer’
- ‘L’Agence Nationale de la Recherche (ANR-16-CE18–0016)
This publication has 11 references indexed in Scilit:
- Oncolytic viruses—immunotherapeutics on the riseJournal of Molecular Medicine, 2016
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV MelanomaJournal of Clinical Oncology, 2016
- Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus ImmunotherapyClinical Cancer Research, 2016
- Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsViruses, 2015
- Harnessing the Power of Onco-Immunotherapy with Checkpoint InhibitorsViruses, 2015
- Oncolytic viruses: a new class of immunotherapy drugsNature Reviews Drug Discovery, 2015
- Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical DataHuman Gene Therapy, 2015
- Measles Virus Vaccine–Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic CellsClinical Cancer Research, 2013
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV MelanomaAnnals of Surgical Oncology, 2009
- Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor ImmunityClinical Cancer Research, 2008